Literature DB >> 18328953

Banding and molecular cytogenetic studies detected a CBFB-MYH11 fusion gene that appeared as abnormal chromosomes 1 and 16 in a baby with acute myeloid leukemia FAB M4-Eo.

Maria Luiza Macedo Silva1, Susana C Raimondi, Eliana Abdelhay, Madeleine Gross, Hasmik Mkrtchyan, Amanda Faria de Figueiredo, Raul C Ribeiro, Terezinha de Jesus Marques-Salles, Elaine S Sobral, Marcelo Poirot Gerardin Land, Thomas Liehr.   

Abstract

The acute myeloid leukemia (AML) subtype M4Eo occurs in 5% of all AML cases and is usually associated with either an inv(16)(p13.1q22) or a t(16;16)(p13.1;q22) chromosomal abnormality. At the molecular level, these abnormalities generate a CBFB-MYH11 fusion gene. Patients with this genetic alteration are usually assigned to a low-risk group and thus receive standard chemotherapy. AML-M4Eo is rarely found in infants. We describe clinical, conventional banding, and molecular cytogenetic data for a 12-month-old baby with AML-M4Eo and a chimeric CBFB-MYH11 fusion gene masked by a novel rearrangement between chromosomes 1 and 16. This rearrangement characterizes a new type of inv(16)(p13.1q22) masked by a chromosome translocation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18328953     DOI: 10.1016/j.cancergencyto.2007.12.014

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  2 in total

Review 1.  Advances in molecular genetics and treatment of core-binding factor acute myeloid leukemia.

Authors:  Krzysztof Mrózek; Guido Marcucci; Peter Paschka; Clara D Bloomfield
Journal:  Curr Opin Oncol       Date:  2008-11       Impact factor: 3.645

2.  Unbalanced chromosome 1 abnormalities leading to partial trisomy 1q in four infants with Down syndrome and acute megakaryocytic leukemia.

Authors:  Maria Luiza Macedo Silva; Maria do Socorro Pombo-de-Oliveira; Susana C Raimondi; Hasmik Mkrtchyan; Eliana Abdelhay; Amanda Faria de Figueiredo; Mariana Tavares de Souza; Daniela Ribeiro Ney Garcia; Eliane Maria Soares de Ventura; Adriana Martins de Sousa; Thomas Liehr
Journal:  Mol Cytogenet       Date:  2009-02-19       Impact factor: 2.009

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.